170 related articles for article (PubMed ID: 18848502)
1. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
Ullman T; Croog V; Harpaz N; Hossain S; Kornbluth A; Bodian C; Itzkowitz S
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1225-30; quiz 1177. PubMed ID: 18848502
[TBL] [Abstract][Full Text] [Related]
2. Will a 5-ASA a day keep the cancer (and dysplasia) away?
Rubin DT; Lashner BA
Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
[TBL] [Abstract][Full Text] [Related]
3. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
[TBL] [Abstract][Full Text] [Related]
6. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location.
Goldstone R; Itzkowitz S; Harpaz N; Ullman T
Gastrointest Endosc; 2011 Nov; 74(5):1087-93. PubMed ID: 21907984
[TBL] [Abstract][Full Text] [Related]
7. [Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921656
[No Abstract] [Full Text] [Related]
8. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
Rubin DT; LoSavio A; Yadron N; Huo D; Hanauer SB
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1346-50. PubMed ID: 17059900
[TBL] [Abstract][Full Text] [Related]
9. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
[TBL] [Abstract][Full Text] [Related]
10. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
11. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of DNA methyltransferase-1 in non-neoplastic epithelium helps predict colorectal neoplasia risk in ulcerative colitis.
Fujii S; Katake Y; Tanaka H
Digestion; 2010; 82(3):179-86. PubMed ID: 20588031
[TBL] [Abstract][Full Text] [Related]
13. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.
Bossa F; Latiano A; Rossi L; Magnani M; Palmieri O; Dallapiccola B; Serafini S; Damonte G; De Santo E; Andriulli A; Annese V
Am J Gastroenterol; 2008 Oct; 103(10):2509-16. PubMed ID: 18721243
[TBL] [Abstract][Full Text] [Related]
15. [Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients].
Lakatos L; Mester G; Erdélyi Z; David G; Pandúr T; Balogh M; Fischer S; Vargha P; Lakatos PL
Orv Hetil; 2006 Jan; 147(4):175-81. PubMed ID: 16515026
[TBL] [Abstract][Full Text] [Related]
16. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis.
D'Haens GR; Lashner BA; Hanauer SB
Am J Gastroenterol; 1993 Aug; 88(8):1174-8. PubMed ID: 8338083
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
Kane SV; Cohen RD; Aikens JE; Hanauer SB
Am J Gastroenterol; 2001 Oct; 96(10):2929-33. PubMed ID: 11693328
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.
Matula S; Croog V; Itzkowitz S; Harpaz N; Bodian C; Hossain S; Ullman T
Clin Gastroenterol Hepatol; 2005 Oct; 3(10):1015-21. PubMed ID: 16234048
[TBL] [Abstract][Full Text] [Related]
19. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up.
Bresci G; Parisi G; Gambardella L; Banti S; Bertoni M; Rindi G; Capria A
Int J Clin Pharmacol Res; 1997; 17(1):17-22. PubMed ID: 9403349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
